Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Troubadour 

Sangamo Bioscienes diskutieren

Sangamo Therapeutics Inc.

WKN: 936386 / Symbol: SGMO / Name: Sangamo Therapeutics / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

0,55 €
4,64 %

Buy Sangamo Bioscienes

Buy Sangamo Therapeutics Inc.

Einschätzung Buy
Rendite (%) -63,50 %
Kursziel 15,12
Veränderung
Endet am 27.02.24

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $16.00 price target on the stock.
Ratings data for SGMO provided by MarketBeat

Einschätzung Buy
Rendite (%) -44,86 %
Kursziel 3,63
Veränderung
Endet am 10.08.24

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its price target lowered by analysts at Wells Fargo & Company from $5.00 to $4.00. They now have an "overweight" rating on the stock.
Ratings data for SGMO provided by MarketBeat

Einschätzung Buy
Rendite (%) -44,86 %
Kursziel 9,12
Veränderung
Endet am 11.08.24

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its price target lowered by analysts at Wedbush from $16.00 to $10.00. They now have an "outperform" rating on the stock.
Ratings data for SGMO provided by MarketBeat

Einschätzung Buy
Rendite (%) -41,90 %
Kursziel 4,57
Veränderung
Endet am 14.08.24

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Ratings data for SGMO provided by MarketBeat

Einschätzung Buy
Rendite (%) -41,30 %
Kursziel 6,40
Veränderung
Endet am 15.08.24

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its price target lowered by analysts at Truist Financial Co. from $8.00 to $7.00. They now have a "buy" rating on the stock.
Ratings data for SGMO provided by MarketBeat

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for SGMO provided by MarketBeat

Einschätzung Buy
Rendite (%) 32,08 %
Kursziel 2,79
Veränderung
Endet am 06.11.24

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its price target lowered by analysts at HC Wainwright from $5.00 to $3.00. They now have a "buy" rating on the stock.
Ratings data for SGMO provided by MarketBeat

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for SGMO provided by MarketBeat

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for SGMO provided by MarketBeat

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for SGMO provided by MarketBeat

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for SGMO provided by MarketBeat

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for SGMO provided by MarketBeat

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for SGMO provided by MarketBeat

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for SGMO provided by MarketBeat

Einschätzung Buy
Rendite (%) 36,48 %
Kursziel 2,76
Veränderung
Endet am 19.01.25

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Ratings data for SGMO provided by MarketBeat

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for SGMO provided by MarketBeat

Einschätzung Buy
Rendite (%) 7,50 %
Kursziel 2,79
Veränderung
Endet am 06.02.25

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Ratings data for SGMO provided by MarketBeat

Einschätzung Buy
Rendite (%) -23,37 %
Kursziel 2,78
Veränderung
Endet am 12.02.25

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Ratings data for SGMO provided by MarketBeat